Physician profile
John Haney
NPI 1699719120
$4,432.11
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,287 · 2020: $844 · 2021: $1,479 · 2022: $822.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $832.03 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $651.58 | 2019-2022 | |
| Abbvie INC. | $552.83 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $485.84 | 2019-2021 | |
| Allergan, INC. | $386.82 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $382.78 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $334.64 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $279.19 | 2019-2020 | |
| Lundbeck LLC | $251.95 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $146.10 | 2021 | |
| Alkermes, INC. | $48.00 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.17 | 2019 | |
| Shire North American Group INC | $23.58 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Haney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.